Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
48 hedge funds and large institutions have $33M invested in Viracta Therapeutics, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
2% less capital invested
Capital invested by funds: $33.6M → $33M (-$512K)
6% less call options, than puts
Call options by funds: $511K | Put options by funds: $542K
4% less funds holding
Funds holding: 50 → 48 (-2)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.17M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$136K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$129K |
| 4 |
KAM
Kazazian Asset Management
Fort Lauderdale,
Florida
|
+$75.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$34.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$507K |
| 2 |
SIM
Spark Investment Management
New York
|
-$94K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$87.9K |
| 4 |
TI
Telemetry Investments
New York
|
-$86.9K |
| 5 |
Two Sigma Investments
New York
|
-$70.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$1K | -6 | Closed |
|
|
SCM
52
Southport Capital Management
Chattanooga,
Tennessee
| – | +$152 | +2 | New |
|
VIRX Hedge Fund Activity: Q3 2018 in Review
48 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2018, worth a combined $33M — down 1.5% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of VIRX and 6 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 11 added.
The largest buyer was Great Point Partners, opening a new position worth an estimated $2.17M. The largest seller was Sabby Management, cutting an estimated $507K.
- 48 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2018, down from 50 in Q2 2018.
- Funds reported $33M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2018, down 1.5% quarter-over-quarter.
- 6 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2018 and 7 closed out, a net change of -1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2018 was Great Point Partners, an estimated $2.17M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2018 was Sabby Management, an estimated $507K sold.
Based on aggregated 13F filings for Q3 2018.